Merck KGaA Croissance future

Future contrôle des critères 1/6

Merck KGaA devrait augmenter ses bénéfices et son chiffre d'affaires de 10.7% et de 4.2% par an respectivement. Le BPA devrait croître de de 11% par an. Le rendement des capitaux propres devrait être 12.9% dans 3 ans.

Informations clés

10.7%

Taux de croissance des bénéfices

11.0%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	19.6%
Taux de croissance des recettes	4.2%
Rendement futur des capitaux propres	12.9%
Couverture par les analystes	Good
Dernière mise à jour	18 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

BMV:MRK1 N - Estimations futures des analystes et données financières antérieures (EUR Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	23,045	3,702	3,733	5,255	13
12/31/2025	22,074	3,395	3,304	5,006	14
12/31/2024	21,163	2,945	3,011	4,597	14
9/30/2024	20,963	2,696	2,160	4,408	N/A
6/30/2024	20,870	2,626	2,052	4,205	N/A
3/31/2024	20,820	2,722	1,961	3,966	N/A
12/31/2023	20,993	2,824	1,897	3,784	N/A
9/30/2023	21,428	2,893	1,912	3,746	N/A
6/30/2023	22,061	3,078	2,198	4,042	N/A
3/31/2023	22,327	3,242	2,334	4,272	N/A
12/31/2022	22,232	3,326	2,491	4,259	N/A
9/30/2022	21,785	3,473	2,788	4,289	N/A
6/30/2022	20,952	3,311	2,658	4,204	N/A
3/31/2022	20,254	3,188	2,734	4,240	N/A
12/31/2021	19,687	3,055	3,234	4,616	N/A
9/30/2021	19,072	2,689	3,125	4,859	N/A
6/30/2021	18,546	2,733	3,073	4,562	N/A
3/31/2021	17,795	2,278	2,702	4,177	N/A
12/31/2020	17,534	1,987	2,002	3,477	N/A
9/30/2020	17,317	1,884	1,684	2,879	N/A
6/30/2020	16,924	1,419	1,498	2,640	N/A
3/31/2020	16,776	1,549	1,729	2,879	N/A
12/31/2019	16,152	1,292	1,858	2,856	N/A
9/30/2019	15,658	1,139	1,967	2,906	N/A
6/30/2019	15,354	1,118	1,751	2,706	N/A
3/31/2019	15,096	938	1,425	2,332	N/A
12/31/2018	14,836	1,071	1,270	2,219	N/A
9/30/2018	14,597	1,921	1,031	2,120	N/A
6/30/2018	14,364	2,218	N/A	2,147	N/A
3/31/2018	14,346	2,389	N/A	2,299	N/A
12/31/2017	14,517	2,548	N/A	2,696	N/A
9/30/2017	14,699	1,787	N/A	2,842	N/A
6/30/2017	14,906	1,628	N/A	3,152	N/A
3/31/2017	15,016	1,529	N/A	2,943	N/A
12/31/2016	15,024	1,629	N/A	2,518	N/A
9/30/2016	14,658	1,480	N/A	2,449	N/A
6/30/2016	14,054	1,387	N/A	2,253	N/A
3/31/2016	13,469	1,418	N/A	2,268	N/A
12/31/2015	12,845	1,109	N/A	2,195	N/A
9/30/2015	12,380	1,269	N/A	2,618	N/A
6/30/2015	12,180	1,154	N/A	2,472	N/A
3/31/2015	11,776	1,114	N/A	2,576	N/A
12/31/2014	11,363	1,157	N/A	2,706	N/A
9/30/2014	11,106	1,158	N/A	2,005	N/A
6/30/2014	10,937	1,249	N/A	2,105	N/A
3/31/2014	10,963	1,261	N/A	2,119	N/A
12/31/2013	11,095	1,202	N/A	2,226	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de MRK1 N ( 10.7% par an) est supérieure au taux d'épargne ( 8.1% ).

Bénéfices vs marché: Les bénéfices de MRK1 N ( 10.7% par an) devraient croître plus lentement que le marché MX ( 11.3% par an).

Croissance élevée des bénéfices: Les bénéfices de MRK1 N devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de MRK1 N ( 4.2% par an) devrait croître plus lentement que le marché de MX ( 7.1% par an).

Croissance élevée des revenus: Le chiffre d'affaires de MRK1 N ( 4.2% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de MRK1 N devrait être faible dans 3 ans ( 12.9 %).

Merck KGaA Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Merck KGaA Provides Earnings Guidance for the First Quarter and Full Year of 2021

Recent updates

Merck KGaA to Report Q4, 2024 Results on Mar 06, 2025

Merck KGaA Announces Phase III Maneuver Trial of Pimicotinib

Merck KGaA (XTRA:MRK) completed the acquisition of Unity Semiconductor SAS for €160 million.

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

Merck KGaA, Annual General Meeting, Apr 25, 2025

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Full year 2023 earnings released: EPS: €6.49 (vs €7.65 in FY 2022)

Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Merck KGaA, Annual General Meeting, Apr 26, 2024

Merck Announces CFO Changes

Merck Reportedly to Put Pigments Unit Up for Sale Again

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

Upcoming dividend of €1.85 per share

Now 21% undervalued after recent price drop

Now 22% undervalued

Full year 2021 earnings: Revenues in line with analyst expectations

MERCK Kommanditgesellschaft auf Aktien to Report Nine Months, 2022 Results on Nov 10, 2022

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Merck Launches New, High-Purity Synthetic Cholesterol Product

First quarter 2021 earnings released

Merck KGaA Provides Earnings Guidance for the First Quarter and Full Year of 2021

Merck KGaA Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study

Full year 2020 earnings released: EPS €4.57 (vs €2.97 in FY 2019)

Revenue beats expectations

Merck Enters into Multiple Agreements to Support Efforts to Expand Manufacturing Capacity and Supply of SARS-CoV-2/COVID-19 Medicines and Vaccines

Merck and GPHL Collaborate on Business Innovation and Development in the Greater Bay Area

Day One Biopharmaceuticals Announces Global License Agreement with Merck KGaA, Darmstadt, Germany to Develop and Commercialize Mek Inhibitor Pimasertib

MERCK Kommanditgesellschaft auf Aktien to Report Q3, 2021 Results on Nov 11, 2021

4D Pharma plc Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with Bavencio for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Merck KGaA, Darmstadt, Germany, Announces Management Changes for North America and Global Innovative Medicine Franchises in Healthcare

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance